Upadacitinib

Overview

Upadacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of several autoimmune disorders. It helps in reducing inflammation by targeting specific pathways involved in the inflammatory response.

API suppliers (1)

Suppliers of Upadacitinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• CHANGZHOU PHARMACEUTICAL FACTORYChina2 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Upadacitinib expires 9 Mar 2038 and exclusivity 27 Apr 2032. Generic API sourcing typically opens up once these lapse.

Therapeutic areas